<DOC>
	<DOCNO>NCT02224534</DOCNO>
	<brief_summary>The purpose study evaluate novel role ticagrelor improve long-term LV remodel follow ST-segment elevation myocardial infarction .</brief_summary>
	<brief_title>Ticagrelor Versus Clopidogrel Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction</brief_title>
	<detailed_description>The investigator design HEALING-AMI study compare influence ticagrelor ( 180 mg load 90 mg twice daily maintenance ) vs. clopidogrel ( 600 mg load 75 mg daily maintenance ) long-term left ventricular ( LV ) remodel measure 3D echocardiography STEMI patient undergo primary PCI . The primary objective HEALING-AMI study demonstrate novel role long-term ticagrelor therapy reduce risk LV remodeling , . The secondary objective reveal cross-talk platelet inflammatory process ST-segment elevation myocardial infarction ( STEMI ) patient . Moreover , study determine whether high platelet inhibition ticagrelor culminate protection infarcted myocardium .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ventricular Remodeling</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>18 year old . Firsttime onset STEMI patient uneventfully treat primary PCI within 12 hour onset symptom . Infarctrelated artery TIMI 0 , 1 , 2 grade flow time initial diagnostic angiography ( wire passage ) . proximal midportion lesion epicardial coronary artery . Previous history myocardial infarction . Left bundle branch block ECG time screen . Cardiogenic shock time randomization . Refractory ventricular arrhythmia atrial fibrillation . New York Heart Association class IV congestive heart failure . Severe malignant hypertension ( SBP &gt; 180 and/or DBP &gt; 120 mmHg ) . Fibrinolytic therapy . History hemorrhagic stroke . Intracranial neoplasm , arteriovenous malformation , aneurysm . Ischemic stroke within 3 month prior screen . Platelet count &lt; 100,000/mm3 hemoglobin &lt; 10 g/dL . A need oral anticoagulation therapy safely discontinue duration study . Women know pregnant , give birth within past 90 day , breastfeed . Unable cooperate protocol requirement followup procedure . A history P2Y12 receptor inhibitor pretreatment ( least prior 1 month ) . An increase risk bradycardia . Concomitant therapy strong cytochrome P450 3A inhibitor inducer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ST elevation myocardial infarction .</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Left ventricular remodel</keyword>
	<keyword>Platelet reactivity</keyword>
</DOC>